Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabel Waibel

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Molecular Pharmaceutics|September 26, 2025
Bayesian Optimization for Efficient Multiobjective Formulation Development of BiologicsIsabel Waibel, Timo N Schneider, Fiona J Fischer, et al.
Advanced Therapeutics|November 22, 2024
Controlled Delivery of Paclitaxel via Stable Synthetic Protein NanoparticlesAva Mauser, Isabel Waibel, Kaushik Banerjee, et al.
Mabs|October 4, 2024
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructsItzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Molecular Pharmaceutics|September 26, 2025
Bayesian Optimization for Efficient Multiobjective Formulation Development of BiologicsIsabel Waibel, Timo N Schneider, Fiona J Fischer, et al.
Advanced Therapeutics|November 22, 2024
Controlled Delivery of Paclitaxel via Stable Synthetic Protein NanoparticlesAva Mauser, Isabel Waibel, Kaushik Banerjee, et al.
Mabs|October 4, 2024
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructsItzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, et al.
Pageof 1